Tandon P, et al. - The risk of diarrhea and colitis associated with immune checkpoint inhibitor therapy in patients with advanced melanoma was determined. Diarrhea and colitis were frequently reported in these patients in association with immunotherapy with checkpoint inhibitors and seemed to be most common with cytotoxic T-lymphocyte antigen-4 inhibitors.